MoonLake Immunotherapeutics
MLTXHealthcare|Biotechnology|Switzerland
$20.36
+0.43 (+2.18%)
Tangible Book
$3.52
Earnings Power
$3.55
About
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Stock Price
-58.3%(1Y)
Pipeline Summary
10 total trials1
Phase 1
2
Phase 2
7
Phase 3
0
Phase 4
Active: 2Completed: 5Recruiting: 1ENROLLING_BY_INVITATION: 2
Active Trials (3)
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076Arthritis, Psoriatic
Phase 3Active
Enrollment: 960 participants
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089Arthritis, Psoriatic
Phase 3Recruiting
Enrollment: 600 participants
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671Hidradenitis Suppurativa
Phase 3Active
Enrollment: 35 participants
BioScore
5.7/10
Watchlist
Ownership
Recent Insider Trades
Santos da Silva JorgeSELL
2026-07-0147,775 shares @ $20.03
Bodenstedt MatthiasSELL
2026-06-2239,120 shares @ $22.04
Bodenstedt MatthiasSELL
2026-06-1817,876 shares @ $19.67
Reich KristianSELL
2026-06-17150,000 shares @ $19.01
Bodenstedt MatthiasSELL
2026-05-1113,653 shares @ $20.02
Recent News
2026-07-04 00:34:06
2026-07-02 22:10:24
2026-07-01 14:00:35
2026-06-24 10:52:02
2026-06-24 05:59:48
Data last updated: Jul 13, 2026, 12:46 PM